Kenjo Masahiro, Uno Takashi, Murakami Yuji, Nagata Yasushi, Oguchi Masahiko, Saito Susumu, Numasaki Hodaka, Teshima Teruki, Mitsumori Michihide
Division of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):357-63. doi: 10.1016/j.ijrobp.2009.03.073.
To describe patient characteristics and the process of radiotherapy (RT) for patients with esophageal cancer treated between 1999 and 2001 in Japan.
The Japanese Patterns of Care Study (PCS) Working Group conducted a third nationwide survey of 76 institutions. Detailed information was accumulated on 621 patients with thoracic esophageal cancer who received RT.
The median age of patients was 68 years. Eighty-eight percent were male, and 12% were female. Ninety-nine percent had squamous cell carcinoma histology. Fifty-five percent had the main lesion in the middle thoracic esophagus. Fourteen percent had clinical Stage 0-I disease, 32% had Stage IIA-IIB, 43% had Stage III, and 10% had Stage IV disease. Chemotherapy was given to 63% of patients; 39% received definitive chemoradiotherapy (CRT) without surgery and 24% pre- or postoperative CRT. Sixty-two percent of the patients aged > or =75 years were treated with RT only. Median total dose of external RT was 60 Gy for definitive CRT patients, 60 Gy for RT alone, and 40 Gy for preoperative CRT.
This PCS describes general aspects of RT for esophageal cancer in Japan. Squamous cell carcinoma accounted for the majority of patients. The standard total external RT dose for esophageal cancer was higher in Japan than in the United States. Chemoradiotherapy had become common for esophageal cancer treatment, but patients aged > or =75 years were more likely to be treated by RT only.
描述1999年至2001年期间在日本接受治疗的食管癌患者的特征及放射治疗(RT)过程。
日本医疗模式研究(PCS)工作组对76家机构进行了第三次全国性调查。收集了621例接受RT的胸段食管癌患者的详细信息。
患者的中位年龄为68岁。88%为男性,12%为女性。99%的患者组织学类型为鳞状细胞癌。55%的患者主要病变位于胸段食管中部。14%的患者临床分期为0-I期,32%为IIA-IIB期,43%为III期,10%为IV期。63%的患者接受了化疗;39%接受了无手术的根治性放化疗(CRT),24%接受了术前或术后CRT。62%年龄≥75岁的患者仅接受RT治疗。对于根治性CRT患者,体外RT的中位总剂量为60 Gy,单纯RT为60 Gy,术前CRT为40 Gy。
本PCS描述了日本食管癌RT的一般情况。鳞状细胞癌占大多数患者。日本食管癌的标准体外RT总剂量高于美国。放化疗在食管癌治疗中已很常见,但年龄≥75岁的患者更可能仅接受RT治疗。